Breaking News
Get 40% Off 0
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list
Close

Genmab AS (GMAB)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Genmab AS's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
28.33 -0.20    -0.70%
18/04 - Closed. Currency in USD ( Disclaimer )
Pre Market
28.12
-0.21
-0.74%
4:00:36 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 242,491
  • Bid/Ask: 28.14 / 28.16
  • Day's Range: 28.29 - 28.62
Genmab AS 28.33 -0.20 -0.70%

GMAB Recent Sentiments

 
This page contains information on users’ sentiments for the Genmab AS stock, which are displayed both on charts of different periods of time and on a detailed table.
BearishBullish
Start Date Username Call Open Rate End Date Chg. %
Apr 03, 2024 Gottfried Dunkel   29.35 -3.48%
Mar 08, 2024 Jorge Dicosta   30.08 Mar 11, 2024 @ 31.46 +4.59%
Mar 07, 2024 Lluís Bou   28.00 Mar 11, 2024 @ 31.46 +12.36%
Feb 28, 2024 LUC BEERTEN   27.79 Mar 22, 2024 @ 29.92 -7.66%
Feb 15, 2024 Mária Sárosi   27.59 Feb 19, 2024 @ 28.71 -4.06%
Feb 05, 2024 Jorge Dicosta   27.80 Feb 05, 2024 @ 27.40 -1.44%
Jan 24, 2024 Piero Rebosio   27.53 Jan 29, 2024 @ 27.82 +1.05%
Jan 23, 2024 LUC BEERTEN   27.55 Feb 13, 2024 @ 26.42 +4.10%
Jan 16, 2024 LUC BEERTEN   29.62 Jan 17, 2024 @ 28.95 +2.26%
Oct 26, 2023 LUC BEERTEN   28.70 Nov 30, 2023 @ 31.28 -8.99%
Oct 18, 2023 LUC BEERTEN   29.59 Oct 23, 2023 @ 29.84 -0.84%
Oct 02, 2023 LUC BEERTEN   34.20 Oct 13, 2023 @ 32.70 +4.39%
Aug 04, 2023 Daniel Johnson   37.51 Nov 30, 2023 @ 31.28 -16.61%
May 24, 2023 sergio ferreira   40.78 Nov 30, 2023 @ 31.28 +23.30%
May 11, 2023 Walter Moran   42.13 Nov 30, 2023 @ 31.28 -25.75%
Jan 06, 2023 Werner Schmidt   42.30 Jan 27, 2023 @ 38.87 -8.11%
Dec 12, 2022 Henning Skov   47.06 Dec 12, 2022 @ 46.99 -0.15%
Dec 01, 2022 Werner Schmidt   46.38 Dec 05, 2022 @ 46.20 -0.39%
Nov 11, 2022 Majed Alg   41.62 Dec 02, 2022 @ 47.06 +13.07%
Oct 26, 2022 TOMA REMEMBER...   39.12 Nov 18, 2022 @ 43.54 +11.30%
Aug 10, 2022 Søren Skov   35.50 Sep 02, 2022 @ 35.13 -1.04%
Aug 08, 2022 Mathias Lindmark   34.86 Sep 02, 2022 @ 35.13 +0.77%
Jul 25, 2022 Walter Moran   35.43 Aug 19, 2022 @ 35.89 +1.30%
May 04, 2022 Michael Almskov   32.66 May 30, 2022 @ 30.36 -7.04%
Feb 16, 2022 Kim Andersen   33.97 Mar 11, 2022 @ 31.71 -6.65%
Nov 23, 2021 Søren Skov   38.58 Dec 17, 2021 @ 37.94 +1.66%
Nov 10, 2021 Ole Kjeldsen   41.96 Dec 03, 2021 @ 37.16 -11.44%
Nov 10, 2021 Morten Munk Ebbesen   43.07 Dec 03, 2021 @ 37.16 -13.72%
Oct 25, 2021 正孝 奥   46.50 Nov 19, 2021 @ 41.43 -10.90%
Oct 19, 2021 Tom Maturo   45.37 Nov 12, 2021 @ 43.52 -4.08%
Oct 04, 2021 Vinderslev   42.63 Oct 11, 2021 @ 42.49 -0.33%
Sep 07, 2021 Victoria Nielsen   47.51 Oct 01, 2021 @ 43.16 -9.16%
Aug 20, 2021 Torben Valentin   47.62 Sep 10, 2021 @ 43.98 -7.64%
Aug 11, 2021 Alp Tankisi   44.92 Sep 03, 2021 @ 48.72 +8.46%
Jul 13, 2021 Søren Skov   43.68 Aug 06, 2021 @ 45.60 +4.40%
Jun 30, 2021 Antonio Framis   40.93 Jul 05, 2021 @ 41.61 +1.66%
Jun 30, 2021 Antonio Framis   40.93 Jul 05, 2021 @ 41.61 +1.66%
Jun 22, 2021 Christian Valdivia...   43.19 Jun 28, 2021 @ 42.07 +2.59%
Jun 14, 2021 Søren Skov   44.19 Jul 09, 2021 @ 43.26 -2.10%
Apr 29, 2021 Søren Skov   37.30 May 21, 2021 @ 39.25 +5.23%
Mar 29, 2021 Søren Skov   32.09 Apr 23, 2021 @ 36.81 +14.71%
Mar 16, 2021 Santiago Lozano   33.66 Apr 09, 2021 @ 34.18 +1.54%
Mar 11, 2021 Mathias Lindmark   33.07 Apr 02, 2021 @ 32.94 -0.39%
Mar 04, 2021 Richard Lakerveld   31.81 Mar 26, 2021 @ 33.01 +3.77%
Mar 03, 2021 Antonio Framis   32.76 Mar 26, 2021 @ 33.01 +0.76%
Mar 01, 2021 Søren Skov   34.75 Mar 26, 2021 @ 33.01 -5.01%
Jan 25, 2021 Edna Ranck   42.51 Feb 19, 2021 @ 40.08 -5.72%
Jan 19, 2021 adel Albakouni   44.24 Jan 27, 2021 @ 42.06 -4.93%
Jan 19, 2021 Mark Sultana   44.06 Feb 12, 2021 @ 40.63 -7.78%
Jan 06, 2021 Søren Skov   40.54 Jan 29, 2021 @ 39.68 -2.12%
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

GMAB Comments

Write your thoughts about Genmab AS
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
David Klepetko
klepid Nov 10, 2021 11:45AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
ERs are out https://ir.genmab.com/financial-calendar
Jens Jensen
Jens Jensen Aug 11, 2021 3:39PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
And no debt, $3B cash position, one of the most "trending" technologies around (bispecific antibodies) and an impressive outflux of new drugs via seemingly peerpoor (now that's a nice new word - you're free to use it;-) quality of research. I urge everyone to check it out - heres the Investor Presentation for Q22021 "https://ir.genmab.com/static-files/cac2e584-6554-4637-a367-a5d21abc51e0". Comp value 2day $30B, best realistic ;-) guess is double up in 3-4 yrs. Seriously.
Jens Jensen
Jens Jensen Aug 11, 2021 3:14PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Falling.. standard market reaction these days to good and solid reportings: crazy that is.. in spite of improved revenue outlook, 4 drugs on market (darazalex(need I say more?)+3 soon-to-become-blockbusters) + 1 prob-to-market-in-october (tisotumab vedotin, w Seagen) + 2 new drugs revealed (one of which: inclacumab - a Sickle Cell Disease treatment, outlicensed to Roche and further outlicensed to Global Blood Therapeutics, but none the less - w potential for BB).
BumHunters Archer
JohnJenga Mar 10, 2021 8:45AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
32, 40 again soon
Morten Lyng
Morten Lyng May 28, 2020 4:18PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Luxus
Morten Lyng
Morten Lyng May 26, 2020 6:01PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Going 200 % up in the next 24-30 month
Mirko Prazzoli
Mirko Prazzoli May 12, 2020 12:45PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
what about this stock?
Morten Lyng
Morten Lyng May 02, 2020 3:32AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
The best upcoming medico company for cancer
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email